Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma-Reference-Cited by-同舟云学术

Hypoxic pelvic and limb perfusion with melphalan and mitomycin C for recurrent limb melanoma

Published:2003-02 Issue:1 Volume:13 Page:51-58
ISSN:0960-8931
Container-title:Melanoma Research
language:en
Short-container-title:Melanoma Research

Author:

Guadagni Stefano,Santinami Mario,Patuzzo Roberto,Pilati Pier Luigi,Miotto Diego,Deraco Marcello,Rossi Carlo Riccardo,Fiorentini Giammaria,Di Filippo Franco,Valenti Marco,Amicucci Gianfranco

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Cancer Research,Dermatology,Oncology

Reference31 articles.

1. Hyperthermic antiblastic perfusion in the treatment of local recurrence or “In-transit” metastases of limb melanoma

2. Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanoma

3. Effect of some proliferative and environmental factors on the toxicity of mitomycin C to tumor cellsin vitro

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A Prospective Study of Intraarterial Infusion Chemotherapy in Advanced Wild-Type BRAF Melanoma Patients;Journal of Surgical Research;2021-12

2. Advanced Merkel cell carcinoma of the lower extremity treated with surgery and isolated pelvic and limb perfusion using Melphalan: A case of unexpected long-term survival;International Journal of Surgery Case Reports;2019

3. Does Locoregional Chemotherapy Still Matter in the Treatment of Advanced Pelvic Melanoma?;International Journal of Molecular Sciences;2017-11-09

4. MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study;Melanoma Research;2017-10

5. Surgical versus percutaneous isolated pelvic perfusion (IPP) for advanced melanoma: comparison in terms of melphalan pharmacokinetic pelvic bio-availability;BMC Research Notes;2017-08-15